Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Eric M. Ruderman"'
Autor:
Anna B. Montgomery, Shang Yang Chen, Yidan Wang, Gaurav Gadhvi, Maximilian G. Mayr, Carla M. Cuda, Salina Dominguez, Hadijat-Kubura Moradeke Makinde, Miranda G. Gurra, Alexander V. Misharin, Arthur M. Mandelin, Eric M. Ruderman, Anjali Thakrar, Simran Brar, Mary Carns, Kathleen Aren, Mahzad Akbarpour, Andrew Filer, Saba Nayar, Ana Teososio, Triin Major, Ankit Bharat, G.R. Scott Budinger, Deborah R. Winter, Harris Perlman
Publikováno v:
Cell Reports, Vol 42, Iss 5, Pp 112513- (2023)
Summary: Monocytes are abundant immune cells that infiltrate inflamed organs. However, the majority of monocyte studies focus on circulating cells, rather than those in tissue. Here, we identify and characterize an intravascular synovial monocyte pop
Externí odkaz:
https://doaj.org/article/adaf60afb9b54ac7aee8d7562ca316cc
Autor:
Maria I. Danila, Lang Chen, Eric M. Ruderman, Justin K. Owensby, Ronan O’Beirne, Joshua A. Melnick, Leslie R. Harrold, David Curtis, W. Benjamin Nowell, Jeffrey R. Curtis
Publikováno v:
ACR Open Rheumatology, Vol 4, Iss 4, Pp 279-287 (2022)
Objective This study’s objective was to test whether an online video intervention discussing appropriate treatment escalation improves willingness to change treatment in people living with rheumatoid arthritis (RA). Methods We conducted a controlle
Externí odkaz:
https://doaj.org/article/854aa644f61146d49b75966861b67ded
Autor:
Stephen D. Persell, Ji Young Lee, Dawid Lipiszko, Yaw A. Peprah, Eric M. Ruderman, Michael Schachter, Darcy S. Majka
Publikováno v:
ACR Open Rheumatology, Vol 2, Iss 3, Pp 131-137 (2020)
Objective Rheumatoid arthritis (RA) confers a 1.5‐ to 2.0‐fold increased risk of cardiovascular disease (CVD). A prior multifaceted quality improvement approach to improving CVD preventive care increased CVD risk factor assessments, but there was
Externí odkaz:
https://doaj.org/article/a87a252b93354d2fbd38c9c9e562b1df
Autor:
Ying-Ying Leung, Tatiana V. Korotaeva, Liliana Candia, Susanne Juhl Pedersen, Wilson Bautista Molano, Eric M. Ruderman, Radjesh Bisoendial, Rodolfo Perez-Alamino, Wendy Olsder, Burkhard Möller, Simeon Grazio, Tania Gudu, Girish M. Mody, Carlos Pineda, Helena Raffayova, Sherry Rohekar, Claudia Goldenstein-Schainberg, Sergio R. Gutierrez Urena, Julio César Casasola Vargas, Bhowmik Meghnathi, Roopa Prasad, Pascal Richette, Jose Roberto S. Miranda, Nikolas Malliotis, Ulla Lindqvist, David Simon, Amara Ezeonyeji, Enrique R. Soriano, Oliver FitzGerald
Publikováno v:
Journal of Rheumatology, 50(1), 119-130. Journal of Rheumatology
Leung, Ying-Ying; Korotaeva, Tatiana V; Candia, Liliana; Pedersen, Susanne Juhl; Bautista Molano, Wilson; Ruderman, Eric M; Bisoendia, Radjesh; Perez-Alamino, Rodolfo; Olsder, Wendy; Möller, B; Grazio, Simeon; Gudu, Tania; Mody, Girish M; Pineda, Carlos; Raffayova, Helena; Rohekar, Sherry; Goldenstein-Schainberg, Claudia; Gutierrez Urena, Sergio R; Casasola Vargas, Julio César; Meghnathi, Bhowmik; ... (2023). Management of Peripheral Arthritis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations. The journal of rheumatology, 50(1), pp. 119-130. The Journal of Rheumatology Publishing Company Limited 10.3899/jrheum.220315
Leung, Ying-Ying; Korotaeva, Tatiana V; Candia, Liliana; Pedersen, Susanne Juhl; Bautista Molano, Wilson; Ruderman, Eric M; Bisoendia, Radjesh; Perez-Alamino, Rodolfo; Olsder, Wendy; Möller, B; Grazio, Simeon; Gudu, Tania; Mody, Girish M; Pineda, Carlos; Raffayova, Helena; Rohekar, Sherry; Goldenstein-Schainberg, Claudia; Gutierrez Urena, Sergio R; Casasola Vargas, Julio César; Meghnathi, Bhowmik; ... (2023). Management of Peripheral Arthritis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations. The journal of rheumatology, 50(1), pp. 119-130. The Journal of Rheumatology Publishing Company Limited 10.3899/jrheum.220315
ObjectiveWe aimed to compile evidence for the efficacy and safety of therapeutic options for the peripheral arthritis domain of psoriatic arthritis (PsA) for the revised 2021 Group in Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAP
Autor:
Nilasha Ghosh, Eric M. Ruderman
Publikováno v:
Arthritis Research & Therapy, Vol 19, Iss 1, Pp 1-9 (2017)
Abstract Current classification criteria for axial spondyloarthritis (axSpA) provide for the inclusion of patients with a wide range of presentations and manifestations. While not considered a formal subclassification, patients are often divided into
Externí odkaz:
https://doaj.org/article/18abc1f6d1cc417897e89f423ee2e1a8
Autor:
Maria I. Danila, Lang Chen, Eric M. Ruderman, Justin K. Owensby, Ronan O’Beirne, Joshua A. Melnick, Leslie R. Harrold, David Curtis, W. Benjamin Nowell, Jeffrey R. Curtis
Publikováno v:
ACR Open Rheumatology. 4:279-287
This study's objective was to test whether an online video intervention discussing appropriate treatment escalation improves willingness to change treatment in people living with rheumatoid arthritis (RA).We conducted a controlled, randomized trial a
Publikováno v:
The Journal of rheumatology. 50(1)
Autor:
Eric M, Ruderman, Alexis, Ogdie
Publikováno v:
The Journal of rheumatology. 49(11)
Autor:
George J. Greene, Jennifer L. Beaumont, Emily J. Bacalao, Azra Muftic, Karen Kaiser, Amy Eisenstein, Arthur M. Mandelin, David Cella, Eric M. Ruderman
Publikováno v:
The Journal of Rheumatology. :jrheum.2022-1176
ObjectiveTo evaluate the impact of a patient-centered rheumatoid arthritis (RA) treat to target (T2T) disease management approach on patient outcomes and patient satisfaction with care.MethodsIn this longitudinal, observational pilot study, rheumatol
Autor:
Gerd R. Burmester, Kevin Winthrop, Ricardo Blanco, Peter Nash, Philippe Goupille, Valderilio F. Azevedo, Carlo Salvarani, Andrea Rubbert-Roth, Elizabeth Lesser, Ralph Lippe, Apinya Lertratanakul, Reva M. Mccaskill, John Liu, Eric M. Ruderman
Publikováno v:
Rheumatology and Therapy
Introduction This integrated analysis describes the safety profile of upadacitinib, an oral Janus kinase inhibitor, at 15 and 30 mg once daily for up to 3 years of exposure in patients with active psoriatic arthritis (PsA) who had a prior inadequate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a92e6a9cf37feb42c1ffc1a9df5498d0
https://hdl.handle.net/11380/1280559
https://hdl.handle.net/11380/1280559